Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
A webcast of the fireside chat will be available in the Investors & Media Section of Sagimet’s website at www.sagimet.com, with an archived replay available following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of NASH, for which there are no treatments currently approved in
Contact:
ICR Westwicke
203-682-7167
maria.yonkoski@westwicke.com
![](https://ml.globenewswire.com/media/ZTliMjlhNjgtN2I1Ny00ZmE5LTlhZGYtNDRkNTBhZDlhYzJkLTEyMjAyMDE=/tiny/Sagimet-Biosciences-Inc-.png)
Source: Sagimet Biosciences Inc.